FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBotanix Pharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BOT.AX
Botanix Pharmaceuticals Limited Stock AnalysisComprehensive stock analysis for Botanix Pharmaceuticals Limited (BOT.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBOT.AX
BOT.AX
Botanix Pharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BOT.AX
  1. Home
  2. Stocks
  3. Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited

🇦🇺BOT.AX•ASX

Botanix Pharmaceuticals Limited

🇦🇺BOT.AX•ASX

Your view on BOT.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Botanix Pharmaceuticals Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Howie McKibbon
Headquarters
D2, 661 Newcastle Street, Leederville, WA, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Howie McKibbon
Headquarters
D2, 661 Newcastle Street, Leederville, WA, AU
Description

Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections.

Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis.

Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Botanix Pharmaceuticals Limited. Starting points for Botanix Pharmaceuticals Limited: EPS -AUD 0.03, beta 0.86 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Botanix Pharmaceuticals Limited. Botanix Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Botanix Pharmaceuticals Limited. Trailing twelve-month EPS for Botanix Pharmaceuticals Limited stands at -AUD 0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterJun 2027This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate−AUD 0.01−AUD 0.01−AUD 0.01−AUD 0.00
Lowest estimate−AUD 0.01−AUD 0.01−AUD 0.02−AUD 0.00
Highest estimate−AUD 0.01−AUD 0.01−AUD 0.00−AUD 0.00
Number of analysts1122
A year ago−AUD 0.021−AUD 0.031−AUD 0.031—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterJun 2027This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 22.50MAUD 25.60MAUD 56.07MAUD 104.53M
Lowest estimateAUD 22.50MAUD 25.60MAUD 44.30MAUD 61.10M
Highest estimateAUD 22.50MAUD 25.60MAUD 74.60MAUD 140.50M
Number of analysts1133
A year agoAUD 377597.00AUD 5.41MAUD 34.51M—
Growth vs a year ago+5858.7%+373.1%+62.5%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Botanix Pharmaceuticals Limited. Botanix Pharmaceuticals Limited has reported as a listed company since 1988. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BOT.AX20 companies
Compare BOT.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ACW.AXActinogen Medical LimitedHealthcareBiotechnology—
ARX.AXAroa Biosurgery LimitedHealthcareMedical - Devices—
ATH.AXAlterity Therapeutics LimitedHealthcareBiotechnology—
AVR.AXAnteris Technologies LtdHealthcareMedical - Devices—
DXB.AXDimerix LimitedHealthcareBiotechnology—
MVF.AXMonash IVF Group LimitedHealthcareMedical - Diagnostics & Research—
NYR.AXNyrada Inc.HealthcareBiotechnology—
OCC.AXOrthocell LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PTCTPTC Therapeutics, Inc.HealthcareNASDAQ$5.0B
PTGXProtagonist Therapeutics, Inc.HealthcareNASDAQ$8.3B
PTHSPelthos Therapeutics Inc.HealthcareAMEX$27.9M
PTIXProtagenic Therapeutics, Inc.HealthcareNASDAQ$470,654
PTNPalatin Technologies, Inc.HealthcareNASDAQ$9.2M
PTX.AXPrescient Therapeutics LimitedHealthcareASX—
PULMPulmatrix, Inc.HealthcareNASDAQ$4.9M
PVCTProvectus Biopharmaceuticals, Inc.HealthcareOTC$18.7M
PVLAPalvella Therapeutics, Inc.HealthcareNASDAQ$2.1B
PXMDPaxMedica, Inc. Common StockHealthcareOTC$37,879
PXXLFPoxel S.A.HealthcareOTC$13.4M
PYC.AXPYC Therapeutics LimitedHealthcareASX—
Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Botanix Pharmaceuticals Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Botanix Pharmaceuticals Limited. Coverage tracks Botanix Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Botanix Pharmaceuticals Limited.

BOT.AX AnalysisWeak
Past
1
Growth
3
Health
3
Profit
1
Value
1